← Back to all trials
Completed
NCT00761631
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
Conditions: Healthy Subjects
Sex: All
Ages: 15 Months – 18 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 1200
Sponsor: Pfizer
Location: Central Arkansas Pediatric Clinic Benton Arkansas
Summary
This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.
Eligibility Criteria
Inclusion Criteria:
* Male or female subjects \>15months to \
Source: ClinicalTrials.gov (NCT00761631). StuddyBuddy aggregates publicly available trial information.